A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps
PHASE3
EFC18418 is a multinational, randomized, double-blind, placebo-controlled, ...
Status
Active Not Recruiting
Location
University of Southern California (USC) / Keck Medicine of USC- Site Number : 8400037
A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti--IL-33 mAb) in Participants With Chronic Rhinosinusitis Without Nasal Polyps
PHASE2
ACT18421 is a multinational, randomized, double-blind, placebo-controlled, ...
Status
Completed
Location
Allervie Clinical Research - Birmingham- Site Number : 8400006
A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps
PHASE3
EFC18419 is a multinational, randomized, double-blind, placebo-controlled, ...